Page 1

RESULTS AT 48 WEEKS OF A PHASE IIB EXTENSION STUDY OF THE EXON-SKIPPING DRUG ETEPLIRSEN IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) JR MENDELL, L RODINO-KLAPAC, Z SAHENK, K ROUSH, L BIRD, LP LOWES, L ALFANO, AM GOMEZ, S LEWIS, V MALIK, K SHONTZ, KM FLANIGAN, JR KEAN, HD ALLEN, C SHILLING, COLUMBUS, OH P SAZANI, EM KAYE, CAMBRIDGE, MA

WORLD MUSCLE SOCIETY CONGRESS 2012 PERTH, AUSTRALIA OCTOBER 13, 2012

Profile for Parent Project Muscular Dystrophy

Full 48-week Phase IIb data from eteplirsen study in Duchenne presented at World Muscle Society  

Dr. Jerry Mendell, Director of the Centers for Gene Therapy and Muscular Dystrophy at Nationwide Children's Hospital and principal investiga...

Full 48-week Phase IIb data from eteplirsen study in Duchenne presented at World Muscle Society  

Dr. Jerry Mendell, Director of the Centers for Gene Therapy and Muscular Dystrophy at Nationwide Children's Hospital and principal investiga...

Advertisement